Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world setting

Fig. 4

The data for all remaining clinical outcomes (LCI2.5, ppFEV1, weight z-score, height z-score, BMI z-score) are presented as scatter plots along with the predicted modelled change in clinical outcomes over the study period. The change over time in clinical outcomes is expressed as an annualised slope, which is interpreted as the predicted annual change in the outcome. Study day was defined as the number of days pre/post initiation of LUM/IVA therapy

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us